Hypermarcas
Hypera SA, formerly known as Hypermarcas SA, is a Brazilian pharmaceutical company operating in prescription drugs, over-the-counter medications, and consumer health products. The company develops, manufactures, and markets branded generic pharmaceuticals, OTC health products, skin care items, and nutritional supplements under brands like Neosaldina, Benegrip, and Epocler. Revenue is generated from wholesale product sales through pharmacy chains, healthcare distributors, and retail grocery channels across Brazil. Core end markets encompass individual retail consumers, pharmacy networks, and medical prescription patients in Brazil. Hypera holds the market-leading position as Brazil's largest domestic pharmaceutical company by revenue and volume. The corporation is headquartered in São Paulo, Brazil, and its ordinary shares trade on the B3 stock exchange.
8 of the funds FundTelligence covers report a position in Hypermarcas.
- Legal name
- Hypermarcas SA
- Sector
- Health Care
- Country
- Brazil
- Funds holding it
- 8
Funds holding Hypermarcas
- Templeton BIC Fund — Franklin Templeton · 0.79 % (full portfolio disclosed, September 2026)
- Nordea Stable Emerging Markets — Nordea Funds · 0.46 % (full portfolio disclosed, July 2026)
- Templeton Emerging Markets Smaller Companies Fund — Franklin Templeton · 0.35 % (full portfolio disclosed, September 2026)
- Templeton Emerging Markets Fund — Franklin Templeton · 0.34 % (full portfolio disclosed, September 2026)
- Nordea Stable Return Fund — Nordea Funds · 0.04 % (full portfolio disclosed, July 2026)
- Nordea Stabil Balanceret — Nordea Funds · 0.03 % (full portfolio disclosed, July 2026)
- SEB Emerging Marketsfond — SEB · 0.02 % (full portfolio disclosed, June 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.02 % (full portfolio disclosed, October 2026)